 |
answer text |
<p>The National Institute for Health and Care Excellence (NICE) is the independent
body that guides the National Health Service on funding new medicines, based on clinical
and cost-effectiveness.. The NHS is legally required to fund medicines recommended
by NICE, usually within 3 months of final guidance.</p><p>NICE has recommended abiraterone
for the treatment of metastatic hormone-relapsed prostate cancer before chemotherapy
is indicated and for castration-resistant metastatic prostate cancer previously treated
with a docetaxel-containing regimen. NHS England funds abiraterone in line with NICE’s
recommendations, ensuring access for eligible patients.</p><p>Abiraterone is not licensed
for the treatment of non-metastatic prostate cancer and has therefore not been appraised
by NICE for such use. NHS England is currently considering a clinical policy proposal
for abiraterone as a treatment option for potential use in specific cases. The proposal
is due to be discussed later this month, with potential stakeholder testing by January
2024, if supported.</p>
|
|
